Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lentiglobin
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Bluebird Bio
Deal Size : Undisclosed
Deal Type : Agreement
Details : The two subsidiaries, Hitachi Chemical Advanced Therapeutics Solutions (HCATS) and Apceth Biopharma, will be in charge of late-clinical development and manufacturing of LentiGlobin at facilities in Germany (Apceth) and the U.S. (HCATS).
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 21, 2020
Lead Product(s) : Lentiglobin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Bluebird Bio
Deal Size : Undisclosed
Deal Type : Agreement